Condition: Head & Neck Squamous Cell Carcinoma · Head & Neck Cancer · Postoperative Adjuvant Treatment · Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and neck squamous cell carcinoma who are ineligible for cisplatin chemotherapy. The primary endpoint is disease-free survival (DFS). A total of 185 patients will be enrolled in both the study group and the control group, respectively, with a total planned enrollment of 370 patients. Enrollment is expected to be completed within 2 years, followed by a 3-year follow-up period after the last patient is enrolled.
This description comes directly from the study's public registry record.
Guopei Zhu · 23211699-5665 · antica@gmail.com
Shengjin Dou · 17521066068 · doushengjin@126.com
Always discuss trial participation with your own doctor first.
| Shanghai 9th people's hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07445048